The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...
Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...
Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ER visits and improving treatment ...
The sandwich therapy showed a 2-year overall survival rate of 97% and a leukemia-free survival rate of 72% in Ph-negative ...
This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...
This discussion provides an overview of current treatment standards and practical challenges in managing advanced gastric ...
Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...
“This points more toward a model where the tumor is cleared and the T cells largely go away,” Hinrichs noted in the interview ...
Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...
This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal ...
The FDA has approved selumetinib (Koselugo) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback